Multi-Asset technology pipeline

We are a multi-asset company focused on licensing and developing medical devices with a heavy engineering approach – primarily bio- and neuro-sensor technologies – to address costly unmet medical needs.

After combing through hundreds of technologies that potentially address both defense and civilian medical needs, ECHELON has licensed the first three technologies that fit within our organization’s development strengths and which have strong potential for commercialization and eventual acquisition by strategic partners.

(near infrared spectroscopy)
Wireless Tissue Perfusion Monitor

WiOX™ is a novel tissue perfusion sensor that solves workflow and remote monitoring challenges for post-op flap transfer patients after tumor removal, trauma reconstruction, or breast reconstruction surgeries.

All free tissue flap transfers must be monitored for up to a week post-op to ensure the tissue doesn’t die. This takes round-the-clock hourly monitoring by nurses but is critical because tissue failures can be salvaged if caught immediately.

Self-Contained, Wireless Wearable Cutaneous Flap Monitor

Existing monitoring devices are hard-wired to bedside consoles and are prone to frequent false alerts due to patient movement and cable torquing, which dislodges the sensor. Frequent false alerts are stressful to patients, nurses and surgeons, and are costly to investigate in order to corroborate or dismiss. If the patient has to go back into surgery for investigation, it adds thousands of dollars to the cost of care.

There is an unmet need for a wireless, wearable monitor that continuously and accurately measures tissue oxygenation and can be checked remotely by surgeons or nurses on their phone, tablet or computer station.

WiOX™ is the first and only wireless, wearable, disposable perfusion monitoring device with market opportunities in surgical tissue transfers, peripheral arterial disease (PAD) revascularization, acute compartment syndrome (ACS), and
solid organ transplants.

The WiOX™ device provides the only tissue monitoring platform that can address both cutaneous and buried muscle flaps, with the potential to consolidate and expand the post-op tissue monitoring market.

Mercury Patch™ Wireless
Pressure Injury Monitor

Mercury Patch™ addresses the massive annual mortality and cost burden to hospitals and LTC facilities from pressure ulcers. Each year, 60,000 people in the US die from pressure ulcers – that’s more deaths than from colorectal cancer. The cost burden of pressure injuries to hospitals is >$20B per year. Those costs are borne by the facility, since CMS has determined that pressure ulcers are events that should never happen and thus will not pay.

Pressure sores can form in less than 2 hours but may not be evident for days, making early detection often impossible. Commonly used risk assessment tools like the Braden scales miss 60% of patients who go on to develop pressure ulcers. Current monitoring technologies that attempt to gather more interactive patient data are ineffective and/or extremely expensive.

There is an unmet need for a less costly, wireless, widely implementable monitoring sensor that can measure and predict pressure ulcer problems before they form, to integrate into nursing protocols for preventative treatment.

Mercury Patch™ is the first and only wireless, flexible, disposable sensor for prediction and prevention of pressure injuries and ulcers. Mercury Patch™ fits easily over the sacral dressing and measures pressure points for patients who are either lying or sitting for long periods of time, including surgical recovery patients, critically ill or long-term care patients, paraplegics and quadriplegics.

Self-Contained, Wireless, Disposable, Flexible Pressure Monitor

AwakeOSA™ Rapid Daytime Diagnostic
Test for Obstructive Sleep Apnea

AwakeOSA™ is a totally new way to quickly detect sleep
disorders, which can negatively affect performance readiness for soldiers, as well as cause or worsen numerous costly chronic comorbid conditions for people with obstructive sleep apnea.

$4B a year is spent on diagnostic tests for obstructive sleep apnea (OSA), but it is estimated that as many as 20M people in the US remain undiagnosed and untreated. Studies have documented the serious comorbid health implications and cost burdens from untreated OSA, including hypertension, diabetes, obesity, stroke, cardiovascular disease, depression, and Alzheimer’s Disease, among others. Sleep disorders are also the #1 cause of lost productivity in the workplace.

There is an unmet need to easily and cost-effectively screen and diagnose people with OSA who will benefit from treatment.

AwakeOSA™ is being developed as the first and only rapid daytime diagnostic test for obstructive sleep apnea.

  • Does not require an overnight sleep test
  • Records and analyzes breathing sounds in the context of anthropometric data
  • Extracts specific tracheal breathing characteristics that are unique to upper airway deformities found in people with moderate-to-severe OSA